Cellectis Stock Soars 10% at Close Due to Scientific Breakthrough

Significant Daily and Weekly Gains

Cellectis stock rose by 10.12% this Thursday to close at 4.30 euros, after having already jumped by 10% the previous day. This dynamic is part of a marked upward trend, with gains of 29.52% over the week and 62.57% over three months. Trading volumes accounted for 1.67% of the capital, reflecting moderate investor interest. The biotech benefited from the publication in Nature Communications of an article demonstrating that single-stranded circular DNA (CssDNA) is an effective non-viral template for gene insertion in hematopoietic stem cells. The CssDNA method achieved an insertion efficiency 3 to 5 times higher than that of single-stranded linear DNA, with rates exceeding 40%. This breakthrough could represent an alternative to viral vectors, which are a source of safety concerns. Financially, Cellectis had cash reserves of 225 million dollars as of September 30, 2025, compared to 264 million on December 31, 2024, with financial visibility extended until the second half of 2027. The company remains focused on the development of its candidate product lasmé-cel in acute lymphoblastic leukemia, with a pivotal Phase 2 expected in the second half of 2025.

Technical Analysis Reveals Bullish Acceleration

Technical analysis reveals a stock in a phase of bullish acceleration. The RSI has reached 74, a level close to the overbought zone, indicating strong buying momentum but also suggesting caution in the short term. The price is now above its 50-day moving average established at 3.15 euros, confirming the strength of the trend. The resistance threshold of 4.07 euros was crossed during this session, potentially paving the way for further gains. The MACD shows a positive histogram at 0.08, with the MACD line at 0.12 above the signal line at 0.04, signaling the persistence of bullish momentum. However, the stock displays high volatility of 22.57% over a month, characteristic of small-cap biotechs. The negative beta of -0.39 indicates an inverse correlation with the market, with the CAC 40 having risen by 0.34% during the session compared to 10.12% for Cellectis. The Bollinger Bands, ranging from 2.63 to 3.74 euros, were exceeded by the price, illustrating the magnitude of the ongoing movement. The Schoenberg signal confirms a buy recommendation in this supportive technical context.

Surge Amid Favorable Context for Gene Therapy Biotechs

This surge occurs in a favorable context for biotechnology companies specializing in gene therapies. Cellectis, which develops allogeneic immunotherapies based on CAR-T cells, benefits from increased visibility among investors. The company is set to present new data at the American Society of Hematology congress in early December in Orlando, a closely watched event in the sector. The strategic partnership with AstraZeneca, which aims to develop up to 10 new cell and gene therapy products in oncology, immunology, and rare genetic diseases, enhances the scientific and commercial credibility of the group's technology platform. In the medium term, the company faces several critical deadlines. An arbitral decision in the dispute with Servier is expected by December 15, 2025, while the launch of the Phase 2 trial for lasmé-cel is expected in the second half of the year. The annual performance of 141.6% contrasts with the 10.39% rise of the CAC 40 over the same period, reflecting investors' appetite for this speculative but innovation-rich file.